Tranylcypromine in social phobia.

Author: LiebowitzM R, MundimF D, NardiA E, VersianiM

Paper Details 
Original Abstract of the Article :
Thirty-two patients meeting DSM-III criteria for social phobia entered a 1-year drug treatment with tranylcypromine in dosages between 40 and 60 mg/day. After exclusion of the early dropouts, improvement was rated as marked and moderate in 62% and 17% of the sample (N = 29), respectively. Alcohol ab...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/3209719

データ提供:米国国立医学図書館(NLM)

Tranylcypromine for Social Phobia: Seeking a Desert Oasis of Confidence

Social phobia, a debilitating anxiety disorder, can feel as overwhelming as a vast and unforgiving desert. This study, like a clinical trial, explores the effectiveness of tranylcypromine, a monoamine oxidase inhibitor (MAOI), in treating social phobia. The researchers, like skilled desert therapists, sought to understand the potential benefits and risks of tranylcypromine in alleviating the symptoms of social phobia. Their findings, like a well-documented case study, provide valuable insights into the potential of tranylcypromine as a treatment option for social phobia.

A Potential Oasis of Confidence: Tranylcypromine for Social Phobia

The study found that tranylcypromine, like a hidden oasis in the desert, showed promise in treating social phobia, leading to significant improvement in a majority of patients. However, the study also highlighted the importance of careful monitoring for potential side effects and the need for further research to confirm the long-term efficacy and safety of this medication. This research, like a carefully constructed map, guides us towards a better understanding of the potential benefits and challenges of using tranylcypromine for social phobia.

Navigating the Desert of Social Anxiety

The study emphasizes the importance of individualized treatment plans and the need for close collaboration between patients and healthcare professionals. It's like having a skilled guide leading the way through a desert, ensuring that the right path is taken and any potential obstacles are addressed promptly. Consulting a healthcare professional is essential for developing a personalized treatment strategy that can help manage social phobia effectively and improve quality of life.

Dr. Camel's Conclusion

This study, like a desert expedition, explores the use of tranylcypromine for social phobia. The findings suggest that tranylcypromine may offer a potential oasis of confidence for individuals with this condition. However, further research is needed to confirm its long-term efficacy and safety. Navigating the desert of social anxiety requires both therapeutic support and a commitment to self-care, and this research, like a guidepost in the sand, points towards a better understanding of this challenging condition and the potential of tranylcypromine to improve the lives of those affected.

Date :
  1. Date Completed 1989-02-23
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

3209719

DOI: Digital Object Identifier

3209719

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.